Clinical Research Directory
Browse clinical research sites, groups, and studies.
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
Sponsor: Novo Nordisk A/S
Summary
This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health Related Quality of Life (HRQoL) data. This registry will include the entirety of children treated with Norditropin® for short stature due to NS over the inclusion period. The decision to initiate treatment with commercially available Norditropin® is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
221
Start Date
2022-03-16
Completion Date
2028-03-17
Last Updated
2025-09-25
Healthy Volunteers
No
Conditions
Interventions
Norditropin
Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
Locations (3)
Centre Hospitalier Universitaire D'Angers-2
Angers, France
Ap-Hp-Hopital de Bicetre-2
Le Kremlin-Bicêtre, France
Hopital Des Enfants-2
Toulouse, France